Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2006

01-09-2006 | Clinical study

Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer – results of the ALMANAC validation phase

Authors: Amit Goyal, Robert G Newcombe, Alok Chhabra, Robert E Mansel, on behalf of the ALMANAC Trialists Group

Published in: Breast Cancer Research and Treatment | Issue 2/2006

Login to get access
Metadata
Title
Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer – results of the ALMANAC validation phase
Authors
Amit Goyal
Robert G Newcombe
Alok Chhabra
Robert E Mansel
on behalf of the ALMANAC Trialists Group
Publication date
01-09-2006
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9192-1

Other articles of this Issue 2/2006

Breast Cancer Research and Treatment 2/2006 Go to the issue

Preclinical study

Prognostic impact of Skp2 and p27 in human breast cancer

Epidemiology

Incidence and risk factors associated with bilateral breast cancer in area with early age diagnosis but low incidence of primary breast cancer: analysis of 10-year longitudinal cohort in Taiwan

Preclinical investigation

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer

OriginalPaper

Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha

Epidemiology

Chronological changes of clinical characteristics in 31,115 new breast cancer patients among Koreans during 1996–2004

Preclinical study

Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits